Table 4 Reasons for non-compliance with SOGUG guidelines

Hypertension, n cycles (%)

374

227

73

–

–

3

 Basal BP not recorded

–

226 (99.6)

27 (37.0)

–

–

3 (100)

 BP not recorded

363 (97.1)

137 (60.4)

45 (61.6)

–

–

–

 Dose reduction

9 (2.4)

–

1 (1.4)

–

–

–

 Dose interruption

1 (0.3)

–

–

–

–

–

 Treatment discontinuation

2 (0.5)

1 (0.4)

–

–

–

–

Cardiac toxicity, n cycles (%)

518

–

–

–

–

–

 Non-recorded basal LVEF

145 (28.0)

–

–

–

–

–

 LVEF not performed

484 (93.4)

–

–

–

–

–

 Dose reduction

1 (0.2)

–

–

–

–

–

 Dose interruption

1 (0.2)

–

–

–

–

–

 Treatment discontinuation

2 (0.4)

–

–

–

–

–

Hypotyroidism, n cycles (%)

389

–

–

–

–

–

 Basal TSH not recorded

114 (29.3)

–

–

–

–

–

 TSH > 10 mU/l not-performed

358 (92.0)

–

–

–

–

–

 Dose interruption

2 (0.5)

–

–

–

–

–

Diarrhea, n cycles (%)

180

31

36

–

–

–

 Not recorded

165 (91.7)

29 (93.5)

36 (100)

–

–

–

 Dose reduction

12 (6.7)

1 (3.2)

–

–

–

–

 Dose interruption

3 (1.7)

1 (3.2)

–

–

–

–

Hyperglycemia, n cycles (%)

–

–

–

50

33

–

 Not recorded

–

–

–

25 (100)

33 (100)

–

Dyslipemia, n cycles (%)

–

–

–

102

72

–

 Not recorded

–

–

–

102 (100)

72 (100)

–

Pneumonitis, n cycles (%)

–

–

–

71

37

–

 Basal data not recorded

–

–

–

66 (93.0)

35 (94.6)

–

 Follow-up data not recorded

–

–

–

5 (7.0)

1 (2.7)

–

 Treatment discontinuation

–

–

–

2 (2.8)

1 (2.7)

–

Liver toxicity, n cycles (%)

–

–

104

–

–

–

 Basal liver function not recorded

–

–

19 (18.3)

–

–

–

 Liver function not recorded

–

–

81 (77.9)

–

–

–

 ALT increase > 3–8 ULN

–

–

5 (4.8)

–

–

–

 Dose interruption

–

–

2 (1.9)

–

–

–

 Treatment discontinuation

–

–

1 (1.0)

–

–

–

Proteinuria, n cycles (%)

Not performed

–

–

–

–

–

19 (100)